Hepatitis Drugs: Medicare Part D Spending

• 35medicines with Part D spending (calendar year 2024)

Each number has its full source under its own list below.

1. 1EpclusaSofosbuvir/Velpatasvir · $848.72 per unit$758 million
2. 2PromactaEltrombopag Olamine · $408.06 per unit$672.4 million
3. 3VemlidyTenofovir Alafenamide · $47.42 per unit$199 million
4. 4MavyretGlecaprevir/Pibrentasvir · $155.84 per unit$165.3 million
5. 5Sofosbuvir-VelpatasvirSofosbuvir/Velpatasvir · $280.58 per unit$108.5 million
6. 6VoseviSofosbuvir/Velpatas/Voxilaprev · $857.57 per unit$45.2 million
7. 7TwinrixHepatitis A And B Vaccine/PF · $128.58 per unit$38.3 million
8. 8HarvoniLedipasvir/Sofosbuvir · $1,073.72 per unit$35.9 million
9. 9Plegridy PenPEGinterferon Beta-1a · $8,061.76 per unit$31.9 million
10. 10PEGasysPEGinterferon Alfa-2a · $1,473.91 per unit$31 million
11. 11EntecavirEntecavir · $4.15 per unit$27.1 million
12. 12Tenofovir Disoproxil FumarateTenofovir Disoproxil Fumarate · $3.16 per unit$13.7 million
13. 13AlvaizEltrombopag Choline · $175.05 per unit$8.2 million
14. 14Plegridy*PEGinterferon Beta-1a · $8,104.07 per unit$5.6 million
15. 15HavrixHepatitis A Virus Vaccine/PF · $93.83 per unit$5.5 million

Source: Centers for Medicare & Medicaid Services, Medicare Part D Spending by Drug, calendar year 2024. Retrieved 12 Nov 2026.

• Hepatitis B in children under 5

• Infectious diseases
• HIV
• Liver health
• Neonatal
• Oncology